Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16628538 | 0.79 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL16628578 | 0.79 | L3MBTL1 (0.33) | L3MBTL1MEN1GAAKMT2AMCL1 | |
| SCHEMBL29940880 | 0.72 | — | — | |
| SCHEMBL16628593 | 0.71 | PAOX (0.35) | L3MBTL1MEN1GAAKMT2AMCL1 | |
| SCHEMBL16628576 | 0.70 | L3MBTL1 (0.33) | L3MBTL1ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL6261921 | 0.69 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL16628567 | 0.67 | KMT2A (0.36) | KMT2ACA1CA2CA9HTT | |
| SCHEMBL16628620 | 0.66 | KMT2A (0.38) | KMT2AHTTCYP1A2CYP2C19 | |
| SCHEMBL430482 | 0.66 | CXCR4 (0.40) | L3MBTL1ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL4310063 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | Mori, Kunio (JP) | 2017-11-23 | — | — | US | claimed |
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-06-04 | — | — | US | claimed |
| EP-2859962-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-04-15 | — | — | EP | claimed |
| US-11440304-B2 | Laminate and its production method | AGC Inc. (JP) | 2022-09-13 | — | — | US | disclosed |
| EP-3505522-B1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | MORI KUNIO (JP) | 2020-10-14 | — | — | EP | disclosed |
| US-20200164625-A1 | LAMINATE AND ITS PRODUCTION METHOD | AGC Inc. (JP) | 2020-05-28 | — | — | US | disclosed |
| US-10385076-B2 | Surface treatment agent and novel compound | Mori, Kunio (JP) | 2019-08-20 | — | — | US | disclosed |
| EP-3505522-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-2859962-B1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | MORI KUNIO (JP) | 2019-01-23 | — | — | EP | disclosed |
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | Mori, Kunio (JP) | 2017-11-23 | — | — | US | disclosed |
| US-9790242-B2 | Surface treatment method, surface treatment agent, and novel compound | Mori, Kunio (JP) | 2017-10-17 | — | — | US | disclosed |
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2859962-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | EPCAM, ITGAM, MET | L3MBTL1 4696/4885ALDH1A1 963/4885MEN1 1048/4885 |
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | EPCAM, MET, ITGAM | L3MBTL1 4685/4885ALDH1A1 841/4885MEN1 857/4885 |
| US-10385076-B2 | Surface treatment agent and novel compound | EPCAM, MET, ITGAM | L3MBTL1 4685/4885ALDH1A1 841/4885MEN1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.